Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TO

Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximate

Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript

Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the an

TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter   Comm

BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda

Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in

Alignment with FDA on key elements of the study design support planned start of the Phase 2 study in

BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003

Data show clade IIb from 2022 outbreak is 100 to 100,000-fold less virulent than clade IIa from 2003

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or "the Company"), a full

New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of appr

HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluat

Top Wall Street analysts changed outlook on top names. See all changes incl. upgrades, downgrades &a

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys

Analysts changed outlook on top names, including Intel and Arrow Financial. See ratings page. TNXP s

Raymond James analyst Tiago Fauth initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with

BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasda

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares are trading higher Monday after the company

Tonix Pharmaceuticals Holding shares are trading higher Monday after securing second commercial paye

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides

Agreement with second leading group purchasing organization (GPO), effective June 1, 2026, provides

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third

Real-world analysis of three years of closed claims data from Symphony Health, focused on the third

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-

Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-

Real-world analysis of three years of closed claims data from Symphony Health focused on the third y

Real-world analysis of three years of closed claims data from Symphony Health focused on the third y

BERKELEY HEIGHTS, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq

BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq

Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.93) per share which missed the

Tonix Pharmaceuticals Holding shares are trading higher Wednesday after announcing commercial payer

Agreement with leading group purchasing organization (GPO) provides access to approximately 35 milli

TD Cowen analyst Stacy Ku initiates coverage on Tonix Pharmaceuticals (NASDAQ:TNXP) with a Buy ra

Company on track to initiate a randomized, double-blind, placebo-controlled, adaptive Phase 2 field

TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significan

The publication reports findings from a single-center, randomized, open-label, multiple-dose, parall

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Monday morning, hitting a

Intranasal oxytocin blocks the release of calcitonin gene-related peptide (CGRP) in animal models an

Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody

Tonix Pharmaceuticals beats expectations, and Tonmya prescriptions grow, with over 4,200 prescriptio

Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In pos

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a full

TONMYA™ was investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets) and approved by the

Tonix shares fell 2% premarket after the Nasdaq Global Select uplisting, with technical indicators s